EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists

Joseph Correa, Nicole K Brogden

Journal of Pharmacy & Pharmaceutical Sciences · 04.03.2026 · 29

DOI: 10.3389/jpps.2026.15713 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 04.03.2026. Verfasst von Joseph Correa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, IA, United States. Hauptthemen laut MEDLINE: Asthma, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma and allergies are closely related conditions affecting millions of people around the world. Current treatment options cover many classes of drugs for both acute and ongoing conditions. β2-agonists, leukotriene modifiers, and corticosteroids represent some of the common types of drugs utilized in asthma management. These medications are often delivered via inhalation, oral, or parenteral methods, but each of these modalities faces challenges due to improper technique with inhalers, lessened oral bioavailability due to first-pass metabolism, and reduced compliance of injectable medicines. Transdermal drug delivery may offer a beneficial route of administration that overcomes these barriers as a painless, self-administered form that bypasses first-pass metabolism and can reduce dosing frequency with longer drug release profiles and reduced fluctuations in plasma drug levels. In this two-part mini-review series we will summarize the current literature on transdermal systems for asthma and allergy therapy. Here in Part 1, we cover β2-agonists and discuss the potential of transdermal systems for these drugs. While the body of work with transdermal β2-agonists for asthma treatment is limited, there is still evidence that transdermal systems for asthma has potential to greatly shift the field of asthma therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAdrenergic beta-2 Receptor AgonistsAnti-Asthmatic AgentsHumansAdministration, CutaneousAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

asthmabeta agonistdrug deliveryskintransdermal

Substanzen

Adrenergic beta-2 Receptor AgonistsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, IA, United States.
  • Department of Dermatology, University of Iowa, Iowa City, IA, United States.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Correa, J., & Brogden, N. K. (2026). Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists. Journal of Pharmacy & Pharmaceutical Sciences, 29. https://doi.org/10.3389/jpps.2026.15713

Vancouver

Correa J, Brogden NK. Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists. Journal of Pharmacy & Pharmaceutical Sciences. 2026;29. doi:10.3389/jpps.2026.15713

BibTeX
@article{Correa2026,
  author = {Correa, Joseph and Brogden, Nicole K},
  title = {Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  volume = {29},
  doi = {10.3389/jpps.2026.15713}
}
Kostenlos starten →